Press Releases Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Delayed Australian S.E. Other stock markets 12:46:40 2024-05-16 am EDT			5-day change	1st Jan Change
15.34 ^AUD	+1.79%		+0.65%	+53.27%

May. 03	Telix Pharmaceuticals Completes Acquisition of QSAM Biosciences and Drug Samarium-153-DOTMP	MT
Apr. 30	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Telix to Showcase Extensive Urologic Pipeline at AUA Annual Meeting including Phase III ProstACT GLOBAL Study of TLX591	May. 01	AQ
Telix - Notice of Annual General Meeting 2024	Apr. 22	AQ
Q1 2024 Revenue and Business Update	Apr. 17	AQ
TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation	Apr. 15	AQ
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.	Apr. 11	BU
Telix Pharmaceuticals - World First Use of Lightpoint's SENSEI Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	Mar. 27	AQ
World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain	Mar. 26	AQ
QDOSE Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	Mar. 19	AQ
QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy	Mar. 18	AQ
Appointment of Dr Darren Patti to Group Chief Operating Officer	Mar. 11	AQ
Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform	Mar. 04	AQ
Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics	Feb. 26	AQ
Telix 2023 Full Year Results: Inaugural Profit Achieved, Strong Revenue Growth Underpins Investment in Late-stage Pipeline	Feb. 22	AQ
Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	Feb. 07	AQ
QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals	Feb. 07	AQ
Telix Full Year Results 2023 Investor Webcast Notification	Feb. 07	AQ
MAUNA KEA TECHNOLOGIES REPORTS FULL YEAR 2023 SALES OF EUR10.5M, UP +42% VS 2022	Jan. 26	AQ
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)	Jan. 22	AQ
Telix Announces Planned Registered Public Offering and Listing in the United States	Jan. 04	AQ
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Press Releases

Filters